Stockscreener 앱 받기
0.4371
2.36%
0.0171
전일 마감가:
$0.42
열려 있는:
$0.39
하루 거래량:
4.39M
Relative Volume:
0.27
시가총액:
$4.08M
수익:
$9.81M
순이익/손실:
$-26.16M
주가수익비율:
-0.0113
EPS:
-38.77
순현금흐름:
$-17.45M
1주 성능:
+18.79%
1개월 성능:
-6.54%
6개월 성능:
-92.86%
1년 성능:
-95.62%
1일 변동 폭
$0.39
$0.4627
1주일 범위
$0.325
$0.5638
52주 변동 폭
$0.30
$29.00
Reshape Lifesciences Inc Stock (RSLS) Company Profile
명칭
Reshape Lifesciences Inc
전화
949-429-6680
주소
1001 CALLE AMANECER, SAN CLEMENTE
RSLS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RSLS
Reshape Lifesciences Inc
|
0.4357 | 4.08M | 9.81M | -26.16M | -17.45M | -38.77 |
|
ABT
Abbott Laboratories
|
132.56 | 224.65B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
104.41 | 151.13B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
381.21 | 139.34B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
83.73 | 108.80B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
75.39 | 44.25B | 5.54B | 4.18B | 259.90M | 7.00 |
Reshape Lifesciences Inc 주식(RSLS)의 최신 뉴스
Stocktwits Spotlight: NRx, CVS, ReShape Lead Weekly Jump In Health Care Stock Chatter - MSN
STOCKHOLDER ALERT: The M&A Class Action Firm Continues Its Investigation Into The MergerALBT, NDOI, DNB, RSLS - The Malaysian Reserve
ReShape Lifesciences (RSLS) Secures Patent for Innovative Intrag - GuruFocus
ReShape Lifesciences (RSLS) Showcases Promising Diabetes Device at Neuromodulation Event | RSLS Stock News - GuruFocus
ReShape Lifesciences® Presents Pre-clinical Data on Its - GlobeNewswire
Breakthrough Diabetes Treatment: New Neuromodulation Device Eliminates Need for Insulin Injections - Stock Titan
$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger – ALBT, NDOI, DNB, RSLS - GlobeNewswire Inc.
The Psychology of ReShape Lifesciences Inc Inc. (RSLS) Price Performance: Understanding Market Sentiment - investchronicle.com
There is no way ReShape Lifesciences Inc (RSLS) can keep these numbers up - Sete News
Market Resilience: ReShape Lifesciences Inc (RSLS) Finishes Weak at 0.36, Down -0.85 - DWinneX
Checking in on ReShape Lifesciences Inc (RSLS) after recent insiders movement - knoxdaily.com
Closing Figures Unveiled: ReShape Lifesciences Inc (RSLS) Drop -12.17, Closes at 0.39 - DWinneX
ReShape Lifesciences amends asset purchase terms with Ninjour By Investing.com - Investing.com India
ReShape Lifesciences secures patent for intragastric balloon By Investing.com - Investing.com Canada
ReShape Lifesciences amends asset purchase terms with Ninjour - Investing.com
ReShape Lifesciences (RSLS) Advances with New Patent for Intraga - GuruFocus
ReShape Lifesciences® Receives Notice of Allowance for Key U.S. Patent Related to an Intragastric Balloon System - The Manila Times
Revolutionary Weight Loss Tech: ReShape's New Patent Protects Self-Deflating Gastric Balloon Innovation - Stock Titan
ReShape Lifesciences Inc (RSLS)’s highs and lows: A closer look at its stock price fluctuations - uspostnews.com
Press Release Distribution & PR Platform - ACCESS Newswire
ReShape Lifesciences® Reports Year Ended December 31, 2024 Financial Results and Provides Corporate Update - The Globe and Mail
Insider Sale Alert: ReShape Lifesciences Inc [RSLS] – Is it Time to sell? - knoxdaily.com
ReShape Lifesciences skyrockets after receiving U.S. patent for diabetes neuromodulation technology - MSN
ReShape Lifesciences Ignites Retail Frenzy As Stock Soars On US Patent For Diabetes Neuromodulation System - Asianet Newsable
ReShape Shares Soar After USPTO's Notice of Allowance for Diabetes Neuromodulation Patent - marketscreener.com
ReShape Lifesciences secures patent for diabetes treatment By Investing.com - Investing.com South Africa
ReShape Lifesciences Gets USPTO's Notice of Allowance for Diabetes Neuromodulation Patent - marketscreener.com
ReShape Lifesciences (RSLS) Gains on Diabetes Neuromodulation Patent News - GuruFocus
ReShape Lifesciences secures patent for diabetes treatment - Investing.com
ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology - The Manila Times
ReShape Lifesciences® Secures Patent for Innovative Vagal Neuromodulation Device to Treat Type 2 Diabetes with Enhanced Energy Efficiency - Nasdaq
ReShape Lifesciences® Receives Notice of Allowance for - GlobeNewswire
Revolutionary Diabetes Treatment Patent: ReShape's New Tech Uses 90% Less Energy Than Current Solutions - Stock Titan
ReShape Lifesciences, Allarity, Exact Sciences, CVS, AbbVie: 5 Health Care Stocks That Led Retail Message Growth Last Week - MSN
Why Did ReShape Lifesciences Plunge 11.04%? Earnings Miss, Bearish Sentiment - AInvest
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Earnings call transcript: ReShape Lifesciences Q1 2024 sees cost cuts amid revenue drop - Investing.com UK
Reshape Lifesciences Stock Price, Quotes and Forecasts | NASDAQ:RSLS - Benzinga
ReShape Lifesciences Reports 2024 Financial Results and Strategic Updates - TipRanks
Earnings call transcript: ReShape Lifesciences Q1 2024 sees cost cuts amid revenue drop By Investing.com - Investing.com South Africa
Crude Oil Falls Over 4%; Keros Therapeutics Shares Jump - Benzinga
ReShape Lifesciences Shares Surge 82.2% After Partnership Announcement - AInvest
Dow Tumbles Over 800 Points; US Inflation Rate Falls In March - Benzinga
Penny Stock ReShape To Distribute FDA-Cleared Neuromuscular Device In US - Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Why ReShape Lifesciences Shares Are Trading Higher By Over 82%; Here Are 20 Stocks Moving Premarket - Benzinga
ReShape secures exclusive deal for neuromuscular rehab tech By Investing.com - Investing.com India
ReShape Lifesciences to Bring Motion Informatics' Neuromuscular Rehabilitation Devices to US - MarketScreener
ReShape secures exclusive deal for neuromuscular rehab tech - Investing.com Australia
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
ReShape Lifesciences® Partners with Motion Informatics to Bring AI-Driven Neurorehabilitation Technology to the U.S. Market - The Manila Times
Reshape Lifesciences Inc (RSLS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
9.94%
0.00%
자본화:
|
볼륨(24시간):